Content
Search
Navigation
Sitemap

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

News

Show

Sustainability
Financial
Operating News

news from

all companies
Syncona
all Late-stage clinical companies companies
Autolus Therapeutics
Beacon Therapeutics
all Clinical companies companies
iOnctura
Spur Therapeutics
Quell Therapeutics
Anaveon
all Pre-clinical companies companies
Resolution Therapeutics
Purespring Therapeutics
Forcefield Therapeutics
OMass Therapeutics
Mosaic Therapeutics
Kesmalea Therapeutics
Yellowstone Biosciences
Slingshot Therapeutics

10.12.24

Resolution Therapeutics Announces Presentation at Keystone Symposia on Fibrosis

Operating News
Pre-clinical companies
Resolution Therapeutics

10.12.24

Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024

Operating News
Late-stage clinical companies
Autolus Therapeutics

15.10.24

Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa

Operating News
Late-stage clinical companies
Beacon Therapeutics

27.08.24

Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024

Operating News
Late-stage clinical companies
Autolus Therapeutics

30.07.24

Anaveon appoints Dieter Weinand as Chair of its Board of Directors

Operating News
Clinical companies
Anaveon

29.05.24

Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study

Operating News
Clinical companies
Anaveon

Sign-up for company news alerts

Get the latest RNS, company news, share price information and results from Syncona

RNS alerts
Company alerts

Syncona Investment Management Limited
2nd Floor
8 Bloomsbury Street
London
WC1B 3SR

contact@synconaltd.com

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

Copyright © Syncona 2025
Accessibility
Privacy & cookies
Employee privacy notice
Third party privacy notice
Regulatory publications
Modern slavery statement

Syncona Limited is registered in Guernsey no. 55514, registered office Frances House, PO Box 273, Sir William Place, St. Peter Port, Guernsey, GY1 3RD.
Syncona Investment Management Limited is registered in England no. 10497864, 8 Bloomsbury Street, London WC1B 3SR and is authorised and regulated by the FCA. Syncona Limited is managed by Syncona Investment Management Limited.

threethirty.studio

About us
Our people
Portfolio
Sustainability
News and insights
Investors
Contact

GBX 93.10

Change: +0.10 (+0.11%)

Search

Search